Aggressiveness of Care at the End of Life in Cancer Patients

Cancer is the commonest cause of death in Singapore, and many cancer deaths occur in hospital.

Management of cancer patients is getting more complex with constant development of new drugs, interventional procedures and supportive measures. Despite this, the majority of advanced cancer patients will die from their disease or related complications.

There is a lack of data on the utilisation of health resources in advanced cancer patients in this country. In this study the investigators ask themselves how aggressive care was in the last 3 months of the patient's life. The investigators will be collecting data on specific cancer treatments, interventional procedures, and supportive measures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Cancer

Sex eligibility

All sexes

Study type

Observational

Primary location

National University Hospital

Singapore, 119074

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Advanced cancer patients who passed away as an inpatient in NUH, under the department of Haematology Oncology.

Exclusion criteria

Patients with haematologic malignancies.

Treatment and study plan

Primary outcomes

To describe the trends in the aggressiveness of care for advanced cancer patients near the end of life.

Sponsors and collaborators

Lead sponsor

National University Hospital, Singapore

Other

Registry information

Important dates

Study start: 2008
First posted: Sep 18, 2009
Registry last updated: Apr 8, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed